
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36 million. Adaptive Biotechnologies collected $39.47 million in revenue during Q3, but reported earnings showed a $56.00 million loss.